Elimination of unplanned treatment breaks and dose reductions caused by mucositis: Positive implications for survival outcomes and cost reductions using high potency polymerized cross-linked sucralfate in 55 patients undergoing radiation for head and neck cancer with and without chemotherapy
Ricky Wayne McCullough
Korean J Clin Oncol. 2017;13(1):10-24. Published online 2017 Jun 30 DOI: https://doi.org/10.14216/kjco.17002
Citations to this article as recorded by 
Practice insights on patient care—management overview for chemoradiation toxic mucositis—guidelines, guideline-supported therapies and high potency polymerized cross-linked sucralfate (ProThelial)
Ricky W McCullough
Journal of Oncology Pharmacy Practice.2019; 25(2): 409. CrossRef